| 1 | Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study | Coautor: Zatarain-Barrón Z.L., Chamorro D.F., Cardona A.F., Rodríguez J., et al. | 2023 | TARGET ONCOL | WoS-id: 000963668900001
Scopus-id: 2-s2.0-85151725434
| 13 | 15 |
| 2 | Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial | Coautor: Zatarain-Barrón Z.L., Arrieta O., Hernández-Pedro N., Maldonado F., et al. | 2023 | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | WoS-id: 000991124100001
Scopus-id: 2-s2.0-85127328453
| 3 | 4 |
| 3 | Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country | Coautor: Zatarain-Barron L., Cifuentes C., Lombana M., Vargas H., et al. | 2023 | Cancer Control | Scopus-id: 2-s2.0-85157987134
| 0 | 4 |
| 4 | Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial | 2ᵒ autor: Zatarain-Barrón Z.L., Arrieta O., Turcott J.G., Barrón F., et al. | 2022 | JAMA oncology | WoS-id: 000742417500004
Scopus-id: 2-s2.0-85123024456
| 18 | 19 |
| 5 | Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab | Coautor: Zatarain-Barrón Z.L., Burgos R., Cardona A.F., Santoyo N., et al. | 2022 | Frontiers in Oncology | WoS-id: 000745730700001
Scopus-id: 2-s2.0-85123221804
| 5 | 4 |
| 6 | KRAS and MET in non-small-cell lung cancer: two of the new kids on the ?drivers? block | Coautor: Zatarain-Barrón L., Garcia-Robledo J.E., Rosell R., Ruíz-Patiño A., et al. | 2022 | THER ADV RESPIR DIS | WoS-id: 000751857200001
Scopus-id: 2-s2.0-85123905646
| 12 | 13 |
| 7 | Appetite stimulants for patients with cancer: Current evidence for clinical practice | 2ᵒ autor: Zatarain-Barrón Z.L., Turcott J.G., Cárdenas Fernández D., Castañares Bolaños D.T., et al. | 2022 | NUTRITION REVIEWS | WoS-id: 000766811400015
Scopus-id: 2-s2.0-85126152479
| 6 | 9 |
| 8 | p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics | Coautor: Zatarain-Barrón L., Ruiz-Patiño A., Rodríguez J., Cardona A.F., et al. | 2022 | TRANSLATIONAL ONCOLOGY | WoS-id: 000790037000006
Scopus-id: 2-s2.0-85119498132
| 13 | 12 |
| 9 | Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question | Coautor: Zatarain-Barrón L., Ordóñez-Reyes C., Garcia-Robledo J.E., Chamorro D.F., et al. | 2022 | Pharmaceutics | WoS-id: 000818175500001
Scopus-id: 2-s2.0-85132292554
| 22 | 24 |
| 10 | STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP) | Coautor: Zatarain-Barrón L., Cordeiro de Lima V.C., Corassa M., Saldanha E., et al. | 2022 | LUNG CANCER | WoS-id: 000829620600004
Scopus-id: 2-s2.0-85132705659
| 29 | 28 |
| 11 | Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses | 2ᵒ autor: Zatarain-Barrón Z.L., Barrios-Bernal, Pedro, Hernandez-Pedro, Norma, Orozco-Morales, Mario, et al. | 2022 | Pharmaceuticals | WoS-id: 000831526200001
Scopus-id: 2-s2.0-85133477421
| 8 | 12 |
| 12 | Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors | Coautor: Zatarain-Barrón Z.L., Rojas L., Mayorga D., Ruiz-Patiño A., et al. | 2022 | ESMO Open | WoS-id: 000836446200001
Scopus-id: 2-s2.0-85132785142
| 6 | 8 |
| 13 | Lung Cancer in Colombia | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Mejía S.A., Viola L., et al. | 2022 | JOURNAL OF THORACIC ONCOLOGY | WoS-id: 000863994300007
Scopus-id: 2-s2.0-85132872974
| 8 | 7 |
| 14 | Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP) | Coautor: Zatarain-Barrón Z.L., Raez L.E., Arrieta O., Chamorro D.F., et al. | 2022 | Frontiers in Oncology | WoS-id: 000885753100001
Scopus-id: 2-s2.0-85135015966
| 8 | 8 |
| 15 | Prognostic significance of telomerase reverse transcriptase promoter mutations in high grade meningiomas; | Coautor: Zatarain-Barrón L., Cañas A., Jiménez E., Hakim F., et al. | 2022 | Biomedica | WoS-id: 000898827200003
Scopus-id: 2-s2.0-85137288068
| 1 | 1 |
| 16 | Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP) | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Ruiz-Patiño A., Recondo G., et al. | 2022 | CLINICAL LUNG CANCER | Scopus-id: 2-s2.0-85133607813
| 0 | 9 |
| 17 | Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study | Coautor: Zatarain-Barrón Z.L., Blake-Cerda M., Lozano-Ruíz F., Maldonado-Magos F., et al. | 2021 | LUNG CANCER | WoS-id: 000616364800018
Scopus-id: 2-s2.0-85098550476
| 23 | 22 |
| 18 | Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort | 1ᵉʳ autor: Zatarain-Barrón Z.L., Cardona A.F., Diáz-Garciá D., Trejo Rosales R., et al. | 2021 | ONCOLOGY-BASEL | WoS-id: 000645259600001
Scopus-id: 2-s2.0-85105163529
| 2 | 3 |
| 19 | Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab | Coautor: Zatarain-Barron Z.L., Cardona A.F., Ruiz-Patiño A., Ariza S., et al. | 2021 | Case Reports in Oncology | WoS-id: 000648553000061
Scopus-id: 2-s2.0-85102595267
| 7 | 7 |
| 20 | Prophylactic Cranial Irradiation Reduces Brain Metastases and Improves Overall Survival in High-Risk Metastatic Non-Small Cell Lung Cancer Patients: A Randomized phase 2 Study (PRoT-BM trial) | Coautor: Zatarain-Barrón Z.L., Arrieta O., Maldonado F., Turcott J.G., et al. | 2021 | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | WoS-id: 000680259900025
Scopus-id: 2-s2.0-85103432259
| 9 | 15 |
| 21 | Targeted rna-seq reveals the m. Tuberculosis transcriptome from an in vivo infection model | Coautor: Zatarain-Barron, Zyanya L., Cornejo-Granados, Fernanda, Lopez-Leal, Gamaliel, Mata-Espinosa, Dulce A., et al. | 2021 | BIOLOGY-BASEL | WoS-id: 000699324300001
Scopus-id: 2-s2.0-85114325699
| 10 | 12 |
| 22 | Prophylactic Cranial Irradiation in Patients With High-Risk Metastatic Non-Small Cell Lung Cancer: Quality of Life and Neurocognitive Analysis of a Randomized Phase II Study | Coautor: Zatarain-Barrón Z.L., Maldonado F., Gonzalez-Ling A., Oñate-Ocaña L.F., et al. | 2021 | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | WoS-id: 000709361500014
Scopus-id: 2-s2.0-85107669064
| 7 | 7 |
| 23 | Precision oncology in EGFR positive non-small cell lung cancer: Breaking the 10-year barrier-a case report | Coautor: Zatarain-Barrón L., Ordóñez-Reyes C., Ruiz-Patiño A., Arrieta O., et al. | 2021 | Precision Cancer Medicine | Scopus-id: 2-s2.0-85110737438
| 0 | 0 |
| 24 | Baseline Dysgeusia in Chemotherapy-Naïve Non-Small Cell Lung Cancer Patients: Association with Nutrition and Quality of Life | Coautor: Zatarain-Barrón Z.L., Turcott J.G., Juárez-Hernández E., Sánchez-Lara K., et al. | 2020 | NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL | WoS-id: 000477103500001
Scopus-id: 2-s2.0-85068497147
| 12 | 13 |
| 25 | Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP) | Coautor: Zatarain-Barrón Z.L., Ruiz-Patiño A., Arrieta O., Cardona A.F., et al. | 2020 | Thoracic Cancer | WoS-id: 000502076400001
Scopus-id: 2-s2.0-85076407068
| 45 | 43 |
| 26 | Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status | Coautor: Zatarain-Barrón Z.L., Arrieta O., Ramírez-Tirado L.-A., Caballé-Perez E., et al. | 2020 | Thoracic Cancer | WoS-id: 000514153700001
Scopus-id: 2-s2.0-85079895239
| 15 | 17 |
| 27 | Lung cancer in never smokers: The role of different risk factors other than tobacco smoking | Coautor: Zatarain-Barrón Z.L., Corrales L., Rosell R., Cardona A.F., et al. | 2020 | CRIT REV ONCOL HEMAT | WoS-id: 000527295500007
Scopus-id: 2-s2.0-85079121699
| 152 | 162 |
| 28 | Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab - Diagnostic and Therapeutic Challenge: A Case Report | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Ruiz-Patiño A., Ricaurte L., et al. | 2020 | Case Reports in Oncology | WoS-id: 000533875000053
Scopus-id: 2-s2.0-85082519582
| 7 | 7 |
| 29 | Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer-Reply | Coautor y autor de correspondencia: Zatarain-Barrón Z.L., Arrieta O., Ramirez-Tirado L.A. | 2020 | JAMA oncology | WoS-id: 000536236800022
Scopus-id: 2-s2.0-85081683339
| 1 | 1 |
| 30 | New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer | 2ᵒ autor: Zatarain-Barrón Z.L., Arrieta O., Cardona A.F. | 2020 | LANCET ONCOLOGY | WoS-id: 000540084200023
Scopus-id: 2-s2.0-85083829827
| 4 | 4 |
| 31 | Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial | Coautor: Zatarain-Barrón Z.L., Arrieta O., Barrón F., Ramírez-Tirado L.A., et al. | 2020 | JAMA oncology | WoS-id: 000542037700010
Scopus-id: 2-s2.0-85083206884
| 125 | 128 |
| 32 | Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP) | Coautor: Zatarain-Barrón Z.L., Ruiz-Patiño A., Barrón F., Cardona A.F., et al. | 2020 | Thoracic Cancer | WoS-id: 000551478100001
Scopus-id: 2-s2.0-85088524670
| 14 | 13 |
| 33 | Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Arrieta O., Ruiz-Patiño A., et al. | 2020 | THER ADV RESPIR DIS | WoS-id: 000551965800001
Scopus-id: 2-s2.0-85087711760
| 9 | 11 |
| 34 | Mortality and advanced support requirement for patients with cancer with COVID-19: A mathematical dynamic model for latin America | Coautor: Zatarain-Barron Z.-L., Ruiz-Patiño A., Arrieta O., Pino L.E., et al. | 2020 | Jco Global Oncology | WoS-id: 000564860200007
Scopus-id: 2-s2.0-85085855057
| 8 | 8 |
| 35 | Carboplatin plus etoposide or topotecan for small-cell lung cancer | Coautor y autor de correspondencia: Zatarain-Barrón Z.L., Arrieta O., Lara-Mejía L. | 2020 | LANCET ONCOLOGY | WoS-id: 000568490900026
Scopus-id: 2-s2.0-85089940210
| 7 | 7 |
| 36 | Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group | Coautor: Zatarain-Barrón Z.L., Arrieta O., Cardona A.F., Lara-Mejía L., et al. | 2020 | CRIT REV ONCOL HEMAT | WoS-id: 000572848600008
Scopus-id: 2-s2.0-85087481311
| 14 | 17 |
| 37 | Scientific publications in cancer: in Latin America, strong scientific networks increase productivity (the TENJIN study) | Coautor: Zatarain-Barrón Z.L., Ruiz-Patiño A., Cardona A.F., Arrieta O., et al. | 2020 | JOURNAL OF CLINICAL EPIDEMIOLOGY | WoS-id: 000576195200001
Scopus-id: 2-s2.0-85087334646
| 7 | 6 |
| 38 | Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy | Coautor: Zatarain-Barrón Z.L., Barrón F., Sánchez R., Arroyo-Hernández M., et al. | 2020 | Frontiers in Oncology | WoS-id: 000578623200001
Scopus-id: 2-s2.0-85092536744
| 36 | 36 |
| 39 | Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP) | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Ruiz-Patiño A., Arrieta O., et al. | 2020 | Frontiers in Oncology | WoS-id: 000603377100001
Scopus-id: 2-s2.0-85098515273
| 4 | 4 |
| 40 | Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP) | Coautor: Zatarain-Barrón Z.L., Rojas L., Cardona A.F., Trejo-Rosales R., et al. | 2019 | Thoracic Cancer | WoS-id: 000460181700013
Scopus-id: 2-s2.0-85060917696
| 9 | 9 |
| 41 | Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study | Coautor: Zatarain-Barrón Z.L., Arrieta O., Barrón F., Maldonado F., et al. | 2019 | LUNG CANCER | WoS-id: 000463276900010
Scopus-id: 2-s2.0-85061443801
| 44 | 43 |
| 42 | Multigene mutation profiling and clinical characteristics of small-cell lung cancer in never-smokers vs. Heavy smokers (GENO1.3-clicap) | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Rojas L., Ruiz-Patiño A., et al. | 2019 | Frontiers in Oncology | WoS-id: 000464938900001
Scopus-id: 2-s2.0-85067444081
| 22 | 25 |
| 43 | FAACT-Anorexia Cachexia Scale: Cutoff Value for Anorexia Diagnosis in Advanced Non-Small Cell Lung Cancer Patients | Coautor: Zatarain-Barrón Z.L., Turcott J.G., Oñate-Ocaña L.F., Soca-Chafre G., et al. | 2019 | NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL | WoS-id: 000465614600006
Scopus-id: 2-s2.0-85054359141
| 9 | 10 |
| 44 | Challenges and shifting paradigms in clinical trials in oncology: The case for immunological and targeted therapies | Coautor: Zatarain-Barrón Z.L., Sotelo-Rodríguez D.C., Ruíz-Patiño A., Ricaurte L., et al. | 2019 | ecancermedicalscience | WoS-id: 000474526200001
Scopus-id: 2-s2.0-85085971880
| 3 | 6 |
| 45 | Characteristics of non-small cell lung cancer: Differences by sex and hormonal status in a Mexican population | Coautor: Zatarain-Barrón Z.L., Rodríguez-Lara V., Ramírez-Tirado L.A., Barrón F., et al. | 2019 | SALUD PUBLICA DE MEXICO | WoS-id: 000480351800004
Scopus-id: 2-s2.0-85067229525
| 9 | 9 |
| 46 | Squamous cell lung cancer: Genomic evolution and personalized therapy | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Ricaurte L., Arrieta O. | 2019 | SALUD PUBLICA DE MEXICO | WoS-id: 000480351800011
Scopus-id: 2-s2.0-85067233892
| 7 | 8 |
| 47 | Access to lung cancer therapy in the Mexican population: Opportunities for reducing inequity within the health system | 2ᵒ autor: Zatarain-Barrón Z.L., Gerson R., Blanco C., Arrieta O. | 2019 | SALUD PUBLICA DE MEXICO | WoS-id: 000480351800014
Scopus-id: 2-s2.0-85067261054
| 18 | 16 |
| 48 | A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Rojas L., Wills B., et al. | 2019 | CLINICAL & TRANSLATIONAL ONCOLOGY | WoS-id: 000486535700010
Scopus-id: 2-s2.0-85062018458
| 8 | 8 |
| 49 | Lung Cancer in Mexico | 2ᵒ autor: Zatarain-Barrón Z.L., Arrieta O., Aldaco F., Barrón F., et al. | 2019 | JOURNAL OF THORACIC ONCOLOGY | WoS-id: 000487254200021
Scopus-id: 2-s2.0-85072387534
| 17 | 15 |
| 50 | Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared with Tyrosine Kinase Inhibitors Alone in Patients with Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial | Coautor: Zatarain-Barrón Z.L., Arrieta O., Barrón F., Padilla M.-A.S., et al. | 2019 | JAMA oncology | WoS-id: 000509787900020
Scopus-id: 2-s2.0-85072117400
| 132 | 143 |
| 51 | Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Rojas L., Wills B., et al. | 2018 | JOURNAL OF NEURO-ONCOLOGY | WoS-id: 000422788000016
Scopus-id: 2-s2.0-85034849127
| 25 | 27 |
| 52 | The reality of complexity: Concomitant genomic alterations in patients with EGFR mutations | 2ᵒ autor: Zatarain-Barrón Z.L., Cardona A.F., Rojas L., Arrieta O. | 2018 | JOURNAL OF THORACIC DISEASE | WoS-id: 000427737200037
Scopus-id: 2-s2.0-85042103794
| 2 | 2 |
| 53 | Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices | Coautor: Zatarain-Barrón Z.L., Martín C., Cardona A.F., Ruiz-Patinõ A., et al. | 2018 | ONCOLOGY-BASEL | WoS-id: 000431100700006
Scopus-id: 2-s2.0-85046110113
| 10 | 10 |
| 54 | The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments | Coautor: Zatarain-Barrón Z.L., Raez L.E., Cardona A.F., Santos E.S., et al. | 2018 | LUNG CANCER | WoS-id: 000431157800002
Scopus-id: 2-s2.0-85042470292
| 52 | 55 |
| 55 | Extending the curve: Survival of EGFR-mutated lung cancer patients in the 21st century | 2ᵒ autor: Zatarain-Barrón Z.L., Barrón F., Cardona A.F., Arrieta O. | 2018 | JOURNAL OF THORACIC DISEASE | WoS-id: 000431695300058
Scopus-id: 2-s2.0-85045271594
| 9 | 9 |
| 56 | Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation | Coautor: Zatarain-Barrón Z.L., Barrón F., Cardona A.F., Corrales L., et al. | 2018 | JOURNAL OF THORACIC DISEASE | WoS-id: 000431699000027
Scopus-id: 2-s2.0-85046935764
| 15 | 13 |
| 57 | The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial | Coautor: Zatarain-Barrón Z.L., Turcott J.G., del Rocío Guillen Núñez M., Flores-Estrada D., et al. | 2018 | SUPPORTIVE CARE IN CANCER | WoS-id: 000440114100012
Scopus-id: 2-s2.0-85044041612
| 99 | 106 |
| 58 | EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP) | Coautor: Zatarain-Barrón Z.L., Ruiz-Patiño A., Castro C.D., Ricaurte L.M., et al. | 2018 | TARGET ONCOL | WoS-id: 000446890500008
Scopus-id: 2-s2.0-85054579699
| 29 | 0 |
| 59 | Probable hereditary familial overlap syndrome with multiple synchronous lung tumors | 2ᵒ autor: Zatarain-Barrón Z.L., Cardona A.F., Rubio C., Martínez S., et al. | 2018 | LUNG CANCER | WoS-id: 000448100600040
Scopus-id: 2-s2.0-85052498350
| 8 | 7 |
| 60 | Comprehensive review of fetal adenocarcinoma of the lung | Coautor: Zatarain-Barrón Z.L., Ricaurte L.M., Arrieta O., Cardona A.F. | 2018 | Lung Cancer: Targets and Therapy | WoS-id: 000449668700001
Scopus-id: 2-s2.0-85059018115
| 15 | 28 |
| 61 | EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP) | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Rojas L., Freitas H.C., et al. | 2018 | LUNG CANCER | WoS-id: 000450378500038
Scopus-id: 2-s2.0-85054610184
| 50 | 54 |
| 62 | The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy | 2ᵒ autor: Zatarain-Barron Z.L., Hernandez-Martinez J.-M., Cardona A.F., Arrieta O. | 2018 | JOURNAL OF THORACIC DISEASE | WoS-id: 000451389400080
Scopus-id: 2-s2.0-85057428594
| 5 | 3 |
| 63 | Vista/PD-1H: A potential target for non-small cell lung cancer immunotherapy | Coautor: Zatarain-Barrón Z.L., Hernandez-Martinez J.-M., Vergara E., Barrón-Barrón F., et al. | 2018 | JOURNAL OF THORACIC DISEASE | WoS-id: 000456834700028
Scopus-id: 2-s2.0-85059503812
| 14 | 15 |
| 64 | Ramucirumab in the treatment of non-small cell lung cancer | 2ᵒ autor: Zatarain-Barrón Z.L., Arrieta O., Cardona A.F., Carmona A., et al. | 2017 | EXPERT OPINION ON DRUG SAFETY | WoS-id: 000400867200011
Scopus-id: 2-s2.0-85018825910
| 30 | 33 |
| 65 | Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP) | Coautor: Zatarain-Barrón Z.L., Cardona A.F., Arrieta O., Zapata M.I., et al. | 2017 | TARGET ONCOL | WoS-id: 000406317200010
Scopus-id: 2-s2.0-85020865122
| 25 | 24 |
| 66 | Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab | Coautor: Zatarain-Barrón, Z.L., Wills, B., Cardona, A.F., Rojas, L., et al. | 2017 | ANTICANCER RESEARCH | WoS-id: 000416143900061
Scopus-id: 2-s2.0-85032141626
| 10 | 12 |
| 67 | The Role of a Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: Implications for Survival | Coautor: Zatarain-Barrón Z.L., Turcott J.G., Martinez-Samano J.E., Cardona A.F., et al. | | NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL | WoS-id: 000542421100001
Scopus-id: 2-s2.0-85086782015
| 10 | 10 |
| 68 | Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019?Infected Patients With Lung Cancer | Coautor: Zatarain-Barron L., Rolfo C., Cardona A.F., Ruiz-Patiño A., et al. | | JOURNAL OF THORACIC ONCOLOGY | WoS-id: 000582730500016
Scopus-id: 2-s2.0-85088961178
| 9 | 11 |
| 69 | Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP-LATimus) | Coautor: Zatarain-Barrón Z.L., Martín C., Enrico D., Mas L., et al. | | Thoracic Cancer | WoS-id: 000629612900001
Scopus-id: 2-s2.0-85102713564
| 6 | 2 |
ID's SCOPUS 
ORCID's